AbbVie collaboration boosts Halozyme stock
This article was originally published in Scrip
Executive Summary
AbbVie is paying oncology-focused biotech Halozyme Therapeutics $23m upfront, and up to $130m in potential milestone payments for each of up to nine collaboration targets, in order to get access to the company's Enhanze drug delivery platform.
You may also be interested in...
Halozyme's 2017 Includes PEGPH20 Milestones, New Partnership
Halozyme CEO Helen Torley spoke with Scrip about execution of the company's strategy – reworked after her arrival in 2014 – to focus on oncology drug development and partnerships using its Enhanze platform.
Six New Molecules By 2030 – J&J’s Neuroscience Strategy
Can neuroscience be precise? Peter Fang, worldwide VP of neuroscience, explains J&J's approach to precision medicine in Alzheimer’s disease, depression and other neurological conditions.
Accessing Venture Debt From The EIB
Tips from Gergely Krajcsi, senior investment officer at the European Investment Bank, on how biotechs can access loans for faster growth.